Search research articles
Contact Us
Filters
Showing results (1-10 of 48) with videos related to
Page
of 5
Sort By:
Expert Review of Neurotherapeutics
|
April 1, 2011
Pathophysiology, assessment and management of multiple sclerosis spasticity: an update
Judith Haas
Krankenpflege Journal
|
March 7, 2006
[Long-term prevention of MS: effectiveness alone is not enough]
Judith Haas
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
September 21, 2007
A dose comparison study of IVIG in postpartum relapsing-remitting multiple sclerosis
Judith Haas, Otto Roelf Hommes
Expert Review of Neurotherapeutics
|
April 1, 2011
Questions & answers
Judith Haas, Vincenzo Di Marzo, Patrick Vermersch
Journal of the Neurological Sciences
|
March 27, 2007
Rituximab in chronic inflammatory demyelinating polyneuropathy associated with diabetes mellitus
Christoph Münch, Pedros Anagnostou, Robert Meyer, et al.
BMC Neurology
|
May 26, 2023
Fatigue, depression, and product tolerability during long-term treatment with intravenous immunoglobulin (Gamunex® 10%) in patients with chronic inflammatory demyelinating polyneuropathy
Juliane Klehmet, Björn Tackenberg, Judith Haas, et al.
Journal of the Neurological Sciences
|
December 16, 2006
Serum levels of soluble CD95 are not associated with amelioration of multiple sclerosis during pregnancy
Stefan Ehrlich, Judith Haas, Frauke Zipp, et al.
Journal of Neurology
|
March 10, 2009
IVIG trials in MS. Is albumin a placebo?
Otto R Hommes, Judith Haas, Per Soelberg-Sorenson, et al.
Nature Clinical Practice. Rheumatology
|
August 26, 2006
Implant-related inflammatory arthritis
Thomas Dörner, Judith Haas, Christoph Loddenkemper, et al.
Journal of Neurology
|
February 16, 2006
Current issues in immunomodulatory treatment of multiple sclerosis--a practical approach
Martin Stangel, Ralf Gold, Achim Gass, et al.
Page
of 5
Search research articles
Search
Showing results (1-10 of 48) with videos related to
Sort By:
Page
of 5
Expert Review of Neurotherapeutics
|
April 1, 2011
Pathophysiology, assessment and management of multiple sclerosis spasticity: an update
Judith Haas
Krankenpflege Journal
|
March 7, 2006
[Long-term prevention of MS: effectiveness alone is not enough]
Judith Haas
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
September 21, 2007
A dose comparison study of IVIG in postpartum relapsing-remitting multiple sclerosis
Judith Haas, Otto Roelf Hommes
Expert Review of Neurotherapeutics
|
April 1, 2011
Questions & answers
Judith Haas, Vincenzo Di Marzo, Patrick Vermersch
Journal of the Neurological Sciences
|
March 27, 2007
Rituximab in chronic inflammatory demyelinating polyneuropathy associated with diabetes mellitus
Christoph Münch, Pedros Anagnostou, Robert Meyer, et al.
BMC Neurology
|
May 26, 2023
Fatigue, depression, and product tolerability during long-term treatment with intravenous immunoglobulin (Gamunex® 10%) in patients with chronic inflammatory demyelinating polyneuropathy
Juliane Klehmet, Björn Tackenberg, Judith Haas, et al.
Journal of the Neurological Sciences
|
December 16, 2006
Serum levels of soluble CD95 are not associated with amelioration of multiple sclerosis during pregnancy
Stefan Ehrlich, Judith Haas, Frauke Zipp, et al.
Journal of Neurology
|
March 10, 2009
IVIG trials in MS. Is albumin a placebo?
Otto R Hommes, Judith Haas, Per Soelberg-Sorenson, et al.
Nature Clinical Practice. Rheumatology
|
August 26, 2006
Implant-related inflammatory arthritis
Thomas Dörner, Judith Haas, Christoph Loddenkemper, et al.
Journal of Neurology
|
February 16, 2006
Current issues in immunomodulatory treatment of multiple sclerosis--a practical approach
Martin Stangel, Ralf Gold, Achim Gass, et al.
Page
of 5